Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Nightstar Therapeutics PLC (NASDAQ:NITE)

19.45
Delayed Data
As of Oct 18
 +0.10 / +0.52%
Today’s Change
14.56
Today|||52-Week Range
24.94
--
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$543.8M

Company Description

Nightstar Therapeutics is a clinical-stage gene therapy holding company, which engages in the development and commercializing of gene therapies. Its products include NSR-REP1, a treatment of choroideremia; NSR-RPGR, a treatment of X-linked retinitis pigmentosa; and NSR-003, a treatment of a rare inherited macular dystrophy. The company was founded on July 6, 2017 and is headquartered in London, the United Kingdom.

Contact Information

Nightstar Therapeutics PLC
215 Euston Road
London Greater London NW1 2BE
P:442074112077
Investor Relations:

Employees

Shareholders

Mutual fund holders0.04%
Individual stakeholders--
Other institutional--

Top Executives

David A. FellowsChief Executive Officer & Director
Senthil SundaramCFO & Principal Accounting Officer
Aniz GirachChief Medical Officer
Gregory RobinsonChief Scientific Officer